Page 11 - Numinus Bioscience News Today

Non-Traditional Therapies Could Fill Vital Mental Health Needs - FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, March 2, 2021 /PRNewswire/ -- Non-traditional therapies are coming a long way from their stigmatized roots. Rising rates of serious mental health issues and unreliability of traditional mental health treatments have spurred research into treatment forms utilizing once stigmatized and criminalized drugs. The results have been promising enough that the pharmaceuti...

As “Shrooms” Fix the World’s Largest Healthcare Crisis, This Tiny Stock Will Soar InvestorPlace 3/1/2021 1 in 11 Canadians will have PTSD in their lifetime. 1 in 5 Canadians will suffer from addiction. 450,000 people worldwide died from drug use in 2015. 971 million people worldwide suffer from a mental or substance use disorder. These statistics clearly illustrate two things: Mental health and substance abuse is a global epidemic. Current medications are failing to address this epidemi...

relieve anxiety and depression levels in people with life-threatening cancer diagnoses four-times better than traditional antidepressants on the market. That finding corroborates a previous NYU study, which found that psilocybin causes a “ rapid and sustained” reduction in anxiety and depression levels in cancer patients. Meanwhile, a recent UC Davis study found that psychedelic micro-dosing can produce beneficial behavioral effects in patients with mental health disorders. The list of ac...

Mental Health Demand For Development Of Psychedelic Drug Therapies Is Increasing PALM BEACH, Fla., Jan. 12, 2021 /PRNewswire/ -- After being relegated to the margins of sincere scientific examination for about five decades, growing researchers and scientists are exploring the therapeutic value of psychedelic drugs and compounds that could be a new treatment option for people with depression. According to Data Bridge Market Research North America psychedelic drugs market is expected to gain mar...

North America Psychedelic Drugs Market Could Exceed $6.8 Billion By 2027 - Financialnewsmedia.com News Commentary PALM BEACH, Fla., Jan. 6, 2021 /PRNewswire/ -- In the few places where cannabis is legal, it can be incredibly lucrative. In 2019, the nascent worldwide cannabis sector pumped out approximately $15 billion in sales. By 2024, that number is expected to triple. Not bad for an industry that, less than a decade ago, was entirely illegal almost everywhere on Earth and is still outlawed i...

MindMed Will Use the Proceeds of the Offering for Investment in its Digital Medicine Division, for Further Investments in its Project Lucy and Project Layla, for its LSD Micro-Dosing ADHD Trials and for General Working Capital Purposes MindMed (OTCQB:MMEDF) announced that further to its previously announced offering on December 14 and December 15, 2020, it has filed a preliminary short form prospectus with the securities commissions or similar authorities in each province of Canada, other than...

This week, Health Canada opened a public consultation on its “proposal to restore potential access to restricted drugs through the Special Access Program (SAP).” The SAP allows healthcare professionals to request unapproved drugs for patients with serious or life-threatening conditions if other therapies have failed, aren’t suitable or are not available in Canada. The proposal includes bringing MDMA and psilocybin back from a 2013 amendment to the Food and Drug Regulations that restricte...

), which this week acquired Adelia Therapeutics, a transformational move that broadened addressable indications in its pipeline and strengthened its scientific team. Cybin has a three-pillar approach,  its initial sights set on treating major depression disorder (MDD) now expanded to address additional indication as well through innovative psychedelic therapeutics development and unique delivery technologies. Cybin stands shoulder-to-shoulder with peers striving for a world of better mental we...

Healthcare professionals okayed to use magic mushrooms for training in psilocybin therapy Psychologists, psychiatrists, social workers, and nurses are among 17 healthcare professionals granted the exemption by Health Canada this week by Enzo DiMatteo on December 12th, 2020 at 11:00 PM 1 of 1 2 of 1 The use of psychedelics in therapy hit another high this week. A group of 17 healthcare professionals, among them psychologists, psychiatrists, social workers, and nurses, became the first in ...

Share:   First-of-its-kind policy amendment will allow legal access to evidence-based treatments to those in need before formal drug approval  VANCOUVER, BC, Dec. 11, 2020 /CNW/ - .  ("Numinus" or the "Company") (TSXV:NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies, commends Health Canadas leadership for its intention to revise the Special Access Programme (S...